Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
614
173
187
104
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.6%
10 terminated/withdrawn out of 614 trials
91.2%
+4.7% vs industry average
14%
87 trials in Phase 3/4
3%
3 of 104 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (614)
Real-World Case Registry Study on Obesity
Role: collaborator
Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment
Role: collaborator
FMT for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients
Role: lead
Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke
Role: collaborator
Efficacy of Fecal Microbiota Transplantation in ICU Patients With Gastrointestinal Dysfunction-induced Enteral Nutrition Intolerance
Role: lead
AI-Guided Intensified Follow-up After Surgery for Acute Type A Aortic Dissection
Role: collaborator
Spectral Precise Image Study for Brain Tumors
Role: collaborator
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Role: lead
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Role: lead
Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation
Role: lead
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
Role: collaborator
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Role: collaborator
Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics
Role: lead
AutoFUSE or First-Trimester Ultrasound Scan
Role: lead
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
Role: collaborator
A Study of IN026 in Participants With Refractory Gout
Role: lead
A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT
Role: lead
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
Role: lead
A Study of YKST02 in Participants With Primary IgA Nephropathy
Role: lead
Prospective Validation of Engraftment Syndrome Phenotypes and Outcomes After Hematopoietic Stem Cell Transplantation
Role: collaborator